 It has been hard going for long term investors of Adamas Pharmaceuticals ADMS. The stock has been down trending since the start of 2018. However, at long last investors had something to cheer about. The Emeryville, California based micro-cap added a blistering 77 to its share price in the past 3 trading days. Adamas surge came off the back of a Q2 earnings beat. Adamas generated revenue of 18.79 million, almost all of which was from Gocovri, the companys treatment for dyskinesia the uncontrolled movements in Parkinson patients who are taking a levodopa-based therapy.Gocovri brought in revenue of 18 million, up 24 quarter-over-quarter and up by 41 year-over-year, beating the Streets 15.3 million estimate. Adamas also posted a beat on the bottom line, with Q2 GAAP EPS of -0.37 ahead of consensus by 0.24.Gocovri was also responsible for the quarters other highlight. Along with the treatments excellent performance, the FDA accepted Adamas sNDA supplemental new drug application to extend Gocovris label to treat OFF episodes the times when levodopa does not working perfectly - in Parkinsons disease patients receiving the therapy. A PDUFA date is set for February 1, 2021.William Blair analyst Tim Lugo argues that should the FDA approve the label extension, the full range of benefits provided by Gocovri, will become apparent. Overall, Lugo maintains Adamas value is currently going unnoticed by the market.The 5-star analyst said, We believe the initiatives undertaken by new management who joined the company in 2019, such as the sNDA for Gocovris label revision and Gocovri Cares Coordinator Program, are starting to show effect. The cash balance of 103.4 million at the end of the second quarter is sufficient to get the company into 2021 and should provide sufficient runway for continued execution of Gocovri commercialization. With an enterprise value of just over 90 million and Gocovri to bring in an estimated 68.9 million in sales during the year, we believe there remains a deep value disconnect for shares.Accordingly, Lugo rates ADMS shares an Outperform i.e. Buy. Lugo has no fixed price target in mind. To watch Lugos track record, click hereThe rest of the Street, though, sees plenty of upside in the cards. With an average price target of 8.76, the analysts expect shares to surge by an additional 90 over the next 12 months. The optimistic target is extended to Adamas consensus rating: A Strong Buy - based on 3 Buys and 1 Hold. See Adamas stock analysis on TipRanksTo find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. 